The system provides the surgeon with millimeter-level accuracy in identifying areas of the cavity side margins suspected of cancer during surgery. This is achieved through a needle-type sensor equipped with pathology calibration. Additionally, the system incorporates a clinical diagnostic classification that correlates the pathological results of the tested tissues with the peaks of CDP response. This classification is based on the latest revisions of the pathology classification, which includes Ductal Intraepithelial Neoplasia (DIN), Lobular Intraepithelial Neoplasia (LIN), and Fibroepithelial Lesion (FEL). Diagnostic results of the device, calibrated based on the pathology, appear on its display in the form of negative, suspicious and positive responses within 15 seconds. In numerous clinical trials conducted with CDP, the technology was able to detect about 30% of contaminated margins in patients even despite frozen section and permanent pathology, which was not detected by the conventional pathology method. So if CDP is not used, about 30% of patients have high risk or cancer-involved margins inside their bodies, which refers to the effective role of CDP as a surgeon's aid tool during breast cancer surgery to prevent local recurrence. It should be noted that the sensitivity and specificity of the device are 93% and 91%, respectively. The CDP system is currently being used in 20 surgical centers and hospitals in the country.